Evidence map›Paper›PMID 25044061›Full record

ArticleStatistics in medicine2014

Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.

Danjie Zhang, Ming-Hui Chen, Joseph G Ibrahim, Mark E Boye, Ping Wang, Wei Shen

Abstract read
In one paragraph

Article in Statistics in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Diagnostics for a two-stage joint survival model.Communications in statistics: Simulation and computation · 2023
    Article
  8. Article
  9. Bayesian Design of Superiority Trials: Methods and Applications.Statistics in biopharmaceutical research · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review and Comparison of Computational Approaches for Joint Longitudinal and Time-to-Event Models.International statistical review = Revue internationale de statistique · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Danjie ZhangDepartment of Statistics, University of Connecticut, Storrs, NC, 06269, U.S.A.
Ming-Hui Chen
Joseph G Ibrahim
Mark E Boye
Ping Wang
Wei Shen

Funding

Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIDIAN, MARIE, KOSOROK, MICHAEL R · 2010 to 2019
$21.3M
Bayesian Approaches to Model Selection for Survival DataR01GM070335 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI IBRAHIM, JOSEPH G · 2003 to 2019
$4.0M
INFERENCE IN REGRESSION MODELS WITH MISSING COVARIATESR01CA074015 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI IBRAHIM, JOSEPH G · 1997 to 2010
$1.7M
NCI NIH HHS CA 74015NCI NIH HHS P01 CA142538NCI NIH HHS R01 CA074015NIGMS NIH HHS GM 70335NIGMS NIH HHS R01 GM070335
6 · The paper itself

Abstract

Joint models for longitudinal and survival data now have a long history of being used in clinical trials or other studies in which the goal is to assess a treatment effect while accounting for longitudinal assessments such as patient-reported outcomes or tumor response. Compared to using survival data alone, the joint modeling of survival and longitudinal data allows for estimation of direct and indirect treatment effects, thereby resulting in improved efficacy assessment. Although global fit indices such as AIC or BIC can be used to rank joint models, these measures do not provide separate assessments of each component of the joint model. In this paper, we develop a novel decomposition of AIC and BIC (i.e., AIC = AICLong + AICSurv|Long and BIC = BICLong + BICSurv|Long) that allows us to assess the fit of each component of the joint model and in particular to assess the fit of the longitudinal component of the model and the survival component separately. Based on this decomposition, we then propose ΔAICSurv and ΔBICSurv to determine the importance and contribution of the longitudinal data to the model fit of the survival data. Moreover, this decomposition, along with ΔAICSurv and ΔBICSurv, is also quite useful in comparing, for example, trajectory-based joint models and shared parameter joint models and deciding which type of model best fits the survival data. We examine a detailed case study in mesothelioma to apply our proposed methodology along with an extensive set of simulation studies.

Indexed as

Longitudinal StudiesModels, StatisticalSurvival AnalysisAgedAntineoplastic AgentsCisplatinClinical Trials as TopicClinical Trials, Phase III as TopicComputer SimulationFemaleGlutamatesGuanineHumansMaleMesotheliomaNeoplasmsAntineoplastic AgentsCisplatinGlutamatesGuaninePemetrexedAICBICpatient-reported outcome (PRO)shared parameter modeltime-varying covariates modeltrajectory model

Identifiers

PMID25044061
PMCPMC4221436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.